ProQR Therapeutics (PRQR) Stock Overview
A biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PRQR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
ProQR Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.62 |
| 52 Week High | US$3.10 |
| 52 Week Low | US$1.07 |
| Beta | 0.19 |
| 1 Month Change | -18.59% |
| 3 Month Change | -31.93% |
| 1 Year Change | -28.00% |
| 3 Year Change | -44.14% |
| 5 Year Change | -69.72% |
| Change since IPO | -89.00% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge
Jan 13
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 29% Share Price Plunge Could Signal Some Risk
Nov 24Recent updates
Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge
Jan 13ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 29% Share Price Plunge Could Signal Some Risk
Nov 24Is ProQR Therapeutics (NASDAQ:PRQR) Using Debt Sensibly?
Nov 05ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Price Is Out Of Tune With Revenues
Oct 10ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Jun 13Here's Why ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO May Deserve A Raise
May 27New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)
May 09ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 34%
Apr 14Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding
Dec 14There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump
Oct 23ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected
Jul 15Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher
May 29Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13Shareholder Returns
| PRQR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.1% | -1.1% | -0.2% |
| 1Y | -28.0% | 23.6% | 13.5% |
Return vs Industry: PRQR underperformed the US Biotechs industry which returned 23.6% over the past year.
Return vs Market: PRQR underperformed the US Market which returned 13.5% over the past year.
Price Volatility
| PRQR volatility | |
|---|---|
| PRQR Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRQR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PRQR's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 166 | Daniel de Boer | www.proqr.com |
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs.
ProQR Therapeutics N.V. Fundamentals Summary
| PRQR fundamental statistics | |
|---|---|
| Market cap | US$170.66m |
| Earnings (TTM) | -US$50.49m |
| Revenue (TTM) | US$19.06m |
Is PRQR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRQR income statement (TTM) | |
|---|---|
| Revenue | €16.07m |
| Cost of Revenue | €0 |
| Gross Profit | €16.07m |
| Other Expenses | €58.64m |
| Earnings | -€42.57m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 100.00% |
| Net Profit Margin | -264.83% |
| Debt/Equity Ratio | 8.4% |
How did PRQR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/02 21:17 |
| End of Day Share Price | 2026/01/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ProQR Therapeutics N.V. is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Buchanan | Brean Capital |
| Eliana Merle | Cantor Fitzgerald & Co. |
| Steven Seedhouse | Cantor Fitzgerald & Co. |